Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results are reported here. Patients and Methods: Chemotherapy-naïve patients with unresectable, nonsarcomatoid MPM (Eastern Cooperative Oncology Group performance status 0 to 1), stratified by histology (epithelioid or biphasic), were randomly assigned in a 1:1 ratio to up to six cycles of pemetrexed and cisplatin plus nintedanib (200 mg twice daily) or placebo followed by nintedanib plus placebo monotherapy until progression. The primary end point was progression-free survival (PFS). Results: Eighty-seven patients were randomly assigned. The median number of pemetrexed and cisplatin cycles was six; the median treatment duration for nintedanib was 7.8 months and 5.3 months for placebo. Primary PFS favored nintedanib (hazard ratio [HR], 0.56; 95% CI, 0.34 to 0.91; P = .017), which was confirmed in updated PFS analyses (HR, 0.54; 95% CI, 0.33 to 0.87; P = .010). A trend toward improved overall survival also favored nintedanib (HR, 0.77; 95% CI, 0.46 to 1.29; P = .319). Benefit was evident in epithelioid histology, with a median overall survival gain of 5.4 months (HR, 0.70; 95% CI, 0.40 to 1.21; P = .197; median [nintedanib v placebo], 20.6 months v 15.2 months) and median PFS gain of 4.0 months (HR, 0.49; 95% CI, 0.30 to 0.82; P = .006; median [nintedanib v placebo], 9.7 v 5.7 months). Neutropenia was the most frequent grade ≥ 3 adverse event (AE; nintedanib 43.2% v placebo 12.2%); rates of febrile neutropenia were low (4.5% in nintedanib group v 0% in placebo group). AEs leading to discontinuation were reported in 6.8% of those receiving nintedanib versus 17.1% of those in the placebo group. Conclusion: Addition of nintedanib to pemetrexed plus cisplatin resulted in PFS improvement. AEs were manageable. The clinical benefit was evident in patients with epithelioid histology. The confirmatory phase III part of the study is ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056 · cited 1×
“Nintedanib is an oral, twice-daily, angiokinase inhibitor targeting VEGF receptors 1, 2, and3, platelet-derived growth factor receptors a/b, fibroblast growth factor (FGF) receptors 1, 2, and 3, as well as Src and Abl kinase signaling.(13,14) At the time this study was designed, VEGF signaling was known to play an imp…”
BackgroundZalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Self-citationReck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951 · cited 1×
“Liver enzyme elevations have been reported previously with nintedanib in combination with docetaxel and are generally reversible and manageable.(24) Incidences of AEs typically associated with VEGF/VEGF-receptor inhibitors were either balanced between the groups, as in the case of hypertension, or reported in fewer pa…”
BackgroundSelf-citation
Research works printed but not linked: 29
- 10.1371/journal.pone.0145039 · DOI · Paper page
- Robinson BM, 2012, Ann Cardiothorac Surg, 1, 491
- 10.1016/j.jtho.2016.04.028 · DOI · Paper page
- 10.1183/09059180.00007014 · DOI · Paper page
- 10.1093/annonc/mdv199 · DOI · Paper page
- 10.1097/JTO.0b013e318229586e · DOI · Paper page
- 10.1097/JTO.0b013e31825f22ee · DOI
- 10.1097/JTO.0b013e3181ec18db · DOI · Paper page
- 10.1097/JTO.0b013e318248242c · DOI
- 10.1080/14737140.2016.1244008 · DOI
- 10.2147/OTT.S78805 · DOI
- 10.1002/path.824 · DOI · Paper page
- 10.1056/NEJMra050152 · DOI · Paper page
- 10.1002/ijc.10996 · DOI
- 10.1002/dc.20767 · doi:10.1002/dc.20767
- 10.1158/1535-7163.MCT-07-0052 · DOI
- 10.18632/oncotarget.126 · DOI
- 10.1007/s10585-004-3150-2 · doi:10.1007/s10585-004-3150-2
- 10.1093/annonc/mdr596 · DOI
- 10.1093/annonc/mdv286 · DOI
- 10.1158/1078-0432.CCR-09-2944 · DOI
- 10.1038/bjc.2011.440 · DOI
- 10.1093/annonc/mdh059 · DOI · Paper page
- 10.1016/j.anndiagpath.2014.02.005 · DOI
- Laszlo V, Ozsar J, Klikovits T, et al: Preclinical investigation of the therapeutic potential of nintedanib in malignant pleural mesothelioma. 13th International Conference of the International Mesothelioma Interest Group, Birmingham, United Kingdom, May 1-4, 2016 (abstr)
- Lakatos D, Hegedus B, Laszlo V, et al: Nintedanib-induced motility response in mesothelioma cells. Poster presented at the Semmelweis Symposium: Molecular Oncology: from bench to bedside. Budapest, Hungary, November 5-6, 2015
- 10.1016/S1470-2045(15)00366-6 · DOI · Paper page
- 10.2217/lmt.15.33 · DOI
- 10.1634/theoncologist.2016-0121 · DOI
Cited by
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30765-4 · Cited by 454
Self-citationERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00953-2019 · Cited by 273
Self-citationCeresoli, G. L., Aerts, J. G., Dziadziuszko, R., Ramlau, R., Cedres, S., van Meerbeeck, J. P., Mencoboni, M., Planchard, D., Chella, A., Crinò, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30532-7 · Cited by 164
Self-citationMalignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Nicolini, F., Bocchini, M., Bronte, G., Delmonte, A., Guidoboni, M., Crinò, L., & Mazza, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01519 · Cited by 83
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41
Metadata
- Authors
- Grosso, F., Steele, N., Novello, S., Nowak, A. K., Popat, S., Greillier, L., John, T., Leighl, N. B., Reck, M., Taylor, P., Planchard, D., Sørensen, J. B., Socinski, M. A., von Wangenheim, U., Loembé, A. B., Barrueco, J., Morsli, N., & Scagliotti, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-11-01
- Volume
- 35
- Issue
- 31
- Pages
- 3591-3600
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2755663477
- Cited by
- 143
- References
- 4
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. https://app.cochat.ai/papers/10.1200/jco.2017.72.9012
- The paper
- Grosso, F., Steele, N., Novello, S., Nowak, A. K., Popat, S., Greillier, L., John, T., Leighl, N. B., Reck, M., Taylor, P., Planchard, D., Sørensen, J. B., Socinski, M. A., von Wangenheim, U., Loembé, A. B., Barrueco, J., Morsli, N., & Scagliotti, G. (2017). Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.72.9012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.